跳至主要内容
临床试验/CTRI/2023/10/058614
CTRI/2023/10/058614招募中3 期

A prospective, randomised study comparing the therapeutic efficacy and safety of topical, oral and localised intradermal microinjections of tranexamic acid in patients with facial melasma. - NI

Ashutosh Trivedi0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • All adult patients diagnosed with facial melasma

排除标准

  • Children < 18 years of age, pregnant or nursing women or women planning pregnancy during the duration of trial.
  • Patients with Extra - facial melasma
  • Patient unwilling to give consent to be part of trial.
  • Current use of oral or injectable contraceptives, hormone replacement therapy, blood thinning medications, photosensitizing drugs or drugs known to cause hyperpigmentation of skin.
  • Current or previous use of any medical treatment (topical or oral) or cosmetic procedure (chemical peel, Laser, Dermabrasion) for melasma within 9 months of study enrollment.
  • History of thromboembolic disease such as deep vein thrombosis (DVT), >2 spontaneous abortions, pulmonary embolism or cerebral thrombosis, stroke or subarachnoid haemorrhage.
  • Family history of thromboembolic disease.
  • Smoking, tobacco use.
  • Hypersensitivity to tranexamic acid or sunscreen ingredients.
  • Abnormal bleeding profile (PT INR, Bleeding Time, Clotting Time).

研究者

发起方
Ashutosh Trivedi

相似试验